Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Financial Toxicity of FDA-Approved Hematologic Malignancy Drugs: An Epidemiological Analysis of Cost

Charles Weeks, Mahran Shoukier, Mark Dalgetty, Rohan Vuppala, Shreya Desai, Abigayle B Simon, Vamsi K. Kota, Locke Johnson Bryan, Jorge E. Cortes

Blood (2024) 144 (Supplement 1): 7578.

https://doi.org/10.1182/blood-2024-206129

Published: 2024

Journal Articles

Financial Trends of AML Patients over the Past Decade

Mark Dalgetty, Mahran Shoukier, Danielle Bradshaw, Faizan Boghani, Sruthi Athota, Anvay Shah, Meaghan Standridge, Michael Stokes, Mohammad Mian, Ayushi Chauhan, Amany R. Keruakous, Locke Johnson Bryan, Jorge Cortes, Anand Jillella, Vamsi K. Kota

Blood (2023) 142 (Supplement 1): 5876.

https://doi.org/10.1182/blood-2023-191103

Published: 2023

Journal Articles

Representation of the population in need for pivotal clinical trials in lymphomas

Mycal Casey, Lorriane Odhiambo, Nidhi Aggarwal, Mahran Shoukier, K. M. Islam, Jorge Cortes

Blood (2023) 142 (9): 846–855.

https://doi.org/10.1182/blood.2023020052

Published: 2023

Journal Articles

Are Pivotal Trials for Drug Approval for Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms Representative of the Population Affected By These Diseases?

Mahran Shoukier, Monirul Islam, Mycal Casey, Lorriane Odhiambo, Nidhi Aggarwal, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 13200–13201.

https://doi.org/10.1182/blood-2022-162403

Published: 2022

Journal Articles

The Financial Toxicity of FDA-Drugs Approved for Malignant Hematology

Mahran Shoukier, Mycal Casey, Shreya Desai, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 13285–13286.

https://doi.org/10.1182/blood-2022-169316

Published: 2022

Journal Articles

Global Representation in Phase 2 and Phase 3 Clinical Trials for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

Mycal Casey, Lorriane Odhiambo, Nidhi Aggarwal, Mahran Shoukier, KM Islam, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 5274–5275.

https://doi.org/10.1182/blood-2022-167092

Published: 2022

Journal Articles

Time to Abandon the Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy

Zachery Clint Branham, Chijioke Okereke, Mahran Shoukier, Danielle Bradshaw, Ravindra Kolhe, Anand P. Jillella, Vamsi K. Kota

Blood (2022) 140 (Supplement 1): 8929.

https://doi.org/10.1182/blood-2022-164963

Published: 2022

Journal Articles

Are Pivotal Trials for Drugs Approved for Leukemia, Myelodysplastic Syndromes, and Multiple Myeloma Representative of the Population Demographics Affected By These Diseases?

Mycal Casey, Monirul Islam, Mahran Shoukier, Lorriane Odhiambo, Jorge E. Cortes

Blood (2021) 138 (Supplement 1): 846.

https://doi.org/10.1182/blood-2021-151235

Published: 2021

Journal Articles

Racial Variations in Mutational Profile in Newly Diagnosed Acute Myeloid Leukemia Patients

Tahsin Anwar, Mohammed Mian, Mahran Shoukier, Achuta K Guddati, Moinul Hossain, Ravindra Kolhe, MD PhD, Locke J. Bryan, Anand P Jillella, MD, Jorge E. Cortes, MD, Vamsi Kota, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-143329

Published: 2020

Journal Articles

Outcomes of FLT3-Mutated Acute Myeloid Leukemia Patients: A Single Center Real-World Experience

Mahran Shoukier, Vamsi Kota, MD, Ravindra Kolhe, MD PhD, Locke J. Bryan, Anand P Jillella, MD, Jorge E. Cortes, MD

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-135940

Published: 2020

Journal Articles

Clinical or Sub-Clinical Pancreatitis (PA) Associated with Nilotinib (Nb) As Frontline for Chronic Myelogenous Leukemia (CML)

Mahran Shoukier, Hagop M. Kantarjian, Elias Jabbour, MD, Alfonso Quintas-Cardama, Zeev Estrov, Tapan Kadia, Gautam Borthakur, Guillermo Garcia-Manero, Steven M. Kornblau, Elizabeth M Burton, Susan O’Brien, Jorge E. Cortes

Blood (2011) 118 (21): 4443.

https://doi.org/10.1182/blood.V118.21.4443.4443

Published: 2011

Journal Articles

Safety and Efficacy of Frontline Nilotinib (Nb) for Chronic Phase (CP) Chronic Myeloid Leukemia (CML) in Diabetic Patients (pts)

Mahran Shoukier, Hagop M. Kantarjian, Elias Jabbour, Alfonso Quintas-Cardama, Zeev Estrov, Tapan Kadia, Gautam Borthakur, Guillermo Garcia-Manero, Steven M. Kornblau, Elizabeth M Burton, Susan O'Brien, Jorge E Cortes

Blood (2011) 118 (21): 2764.

https://doi.org/10.1182/blood.V118.21.2764.2764

Published: 2011

NARROW

Financial Toxicity of FDA-Approved Hematologic Malignancy Drugs: An Epidemiological Analysis of Cost

Financial Trends of AML Patients over the Past Decade

Representation of the population in need for pivotal clinical trials in lymphomas

Are Pivotal Trials for Drug Approval for Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms Representative of the Population Affected By These Diseases?

The Financial Toxicity of FDA-Drugs Approved for Malignant Hematology

Global Representation in Phase 2 and Phase 3 Clinical Trials for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

Time to Abandon the Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy

Are Pivotal Trials for Drugs Approved for Leukemia, Myelodysplastic Syndromes, and Multiple Myeloma Representative of the Population Demographics Affected By These Diseases?

Racial Variations in Mutational Profile in Newly Diagnosed Acute Myeloid Leukemia Patients

Outcomes of FLT3-Mutated Acute Myeloid Leukemia Patients: A Single Center Real-World Experience

Clinical or Sub-Clinical Pancreatitis (PA) Associated with Nilotinib (Nb) As Frontline for Chronic Myelogenous Leukemia (CML)

Safety and Efficacy of Frontline Nilotinib (Nb) for Chronic Phase (CP) Chronic Myeloid Leukemia (CML) in Diabetic Patients (pts)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only